VJHemOnc is committed to improving our service to you

ESH MM 2018 | Are BCL2 and MCL1 inhibitors the key against myeloma?

VJHemOnc is committed to improving our service to you

Enrique Ocio

Enrique Ocio, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain, highlights how targeting BCL2 and MCL1 provide an important thereapeutic strategy for multiple myeloma (MM). Dr Ocio discusses the overexpression of MCL1 in myeloma cells and its implications for treatment. This interview took place at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter